GREENWICH LIFESCIENCES, INC. Research and Development Expense
GREENWICH LIFESCIENCES, INC. (GLSI) reported Research and Development Expense of $3.56 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-11
- GREENWICH LIFESCIENCES, INC. research and development expense for the quarter ending 2026-06-30 was $3.56M, a 4.16% increase year-over-year.
- GREENWICH LIFESCIENCES, INC. research and development expense for the quarter ending 2026-03-31 was $5.21M, a 129.29% increase year-over-year.
- GREENWICH LIFESCIENCES, INC. research and development expense for the quarter ending 2025-12-31 was $8.27M, a 4.84% decline year-over-year.
- GREENWICH LIFESCIENCES, INC. research and development expense for the quarter ending 2025-09-30 was $3.27M, a 42.54% increase year-over-year.
- GREENWICH LIFESCIENCES, INC. research and development expense for fiscal 2025 was $17.22M, a 11.24% increase from fiscal 2024.
- GREENWICH LIFESCIENCES, INC. research and development expense for fiscal 2024 was $15.48M, a 101.08% increase from fiscal 2023.
- GREENWICH LIFESCIENCES, INC. research and development expense for fiscal 2023 was $7.70M, a 18.89% increase from fiscal 2022.
- GREENWICH LIFESCIENCES, INC. research and development expense for fiscal 2022 was $6.48M, a 81.93% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $3.56M 10-Q · filed 2026-08-11 | $8.77M 10-Q · filed 2026-08-11 | $17.03M derived: sum of 3 quarters · filed 2026-08-11 | $20.30M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2026-03-31 | $5.21M 10-Q · filed 2026-06-04 | $13.47M derived: sum of 2 quarters · filed 2026-06-04 | $16.74M derived: sum of 3 quarters · filed 2026-06-04 | $20.16M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-12-31 | $8.27M derived: 10-K 12 month − 10-K 9 month · filed 2026-06-01 | $11.53M derived: sum of 2 quarters · filed 2026-06-01 | $14.95M derived: sum of 3 quarters · filed 2026-08-11 | $17.22M 10-K · filed 2026-06-01 | ||||
| 2025-09-30 | $3.27M 10-K · filed 2026-06-01 | $3.52M 10-Q · filed 2025-11-14 | $6.68M derived: sum of 2 quarters · filed 2026-08-11 | $8.95M 10-K · filed 2026-06-01 | $9.63M 10-Q · filed 2025-11-14 | $17.64M derived: sum of 4 quarters · filed 2026-08-11 | ||
| 2025-06-30 | $3.42M 10-Q · filed 2026-08-11 | $3.51M 10-Q · filed 2025-08-14 | $5.69M 10-Q · filed 2026-08-11 | $6.11M 10-Q · filed 2025-08-14 | $14.37M derived: sum of 3 quarters · filed 2026-08-11 | $16.67M derived: sum of 4 quarters · filed 2026-08-11 | ||
| 2025-03-31 | $2.27M 10-Q · filed 2026-06-04 | $2.60M 10-Q · filed 2025-05-20 | $10.96M derived: sum of 2 quarters · filed 2026-06-04 | $13.25M derived: sum of 3 quarters · filed 2026-06-04 | $15.56M derived: sum of 4 quarters · filed 2026-06-04 | |||
| 2024-12-31 | $8.69M derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-01 | $10.98M derived: sum of 2 quarters · filed 2026-06-01 | $13.29M derived: sum of 3 quarters · filed 2026-06-01 | $15.48M 10-K · filed 2026-06-01 | $12.95M 10-K · filed 2025-04-15 | |||
| 2024-09-30 | $2.29M 10-Q · filed 2025-11-14 | $4.60M derived: sum of 2 quarters · filed 2025-11-14 | $6.79M 10-Q · filed 2025-11-14 | $9.13M derived: sum of 4 quarters · filed 2025-11-14 | ||||
| 2024-06-30 | $2.31M 10-Q · filed 2025-08-14 | $4.50M 10-Q · filed 2025-08-14 | $6.84M derived: sum of 3 quarters · filed 2025-08-14 | $8.99M derived: sum of 4 quarters · filed 2025-08-14 | ||||
| 2024-03-31 | $2.19M 10-Q · filed 2025-05-20 | $4.53M derived: sum of 2 quarters · filed 2025-05-20 | $6.69M derived: sum of 3 quarters · filed 2025-05-20 | $8.07M derived: sum of 4 quarters · filed 2025-05-20 | ||||
| 2023-12-31 | $2.33M derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-15 | $4.49M derived: sum of 2 quarters · filed 2025-04-15 | $5.87M derived: sum of 3 quarters · filed 2025-04-15 | $7.70M 10-K · filed 2025-04-15 | ||||
| 2023-09-30 | $2.16M 10-Q · filed 2024-11-14 | $3.54M derived: sum of 2 quarters · filed 2024-11-14 | $5.37M 10-Q · filed 2024-11-14 | $7.82M derived: sum of 4 quarters · filed 2024-11-14 | ||||
| 2023-06-30 | $1.38M 10-Q · filed 2024-08-14 | $3.21M 10-Q · filed 2024-08-14 | $5.67M derived: sum of 3 quarters · filed 2024-08-14 | $7.39M derived: sum of 4 quarters · filed 2024-08-14 | ||||
| 2023-03-31 | $1.83M 10-Q · filed 2024-05-20 | $4.29M derived: sum of 2 quarters · filed 2024-05-20 | $6.01M derived: sum of 3 quarters · filed 2024-05-20 | $6.64M derived: sum of 4 quarters · filed 2024-05-20 | ||||
| 2022-12-31 | $2.46M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-15 | $4.18M derived: sum of 2 quarters · filed 2024-04-15 | $4.81M derived: sum of 3 quarters · filed 2024-04-15 | $6.48M 10-K · filed 2024-04-15 | ||||
| 2022-09-30 | $1.72M 10-Q · filed 2023-10-19 | $2.36M derived: sum of 2 quarters · filed 2023-10-19 | $4.02M 10-Q · filed 2023-10-19 | $6.08M derived: sum of 4 quarters · filed 2023-10-19 | ||||
| 2022-06-30 | $633.25K 10-Q · filed 2023-08-21 | $2.29M 10-Q · filed 2023-08-21 | $4.36M derived: sum of 3 quarters · filed 2023-08-21 | $5.02M derived: sum of 4 quarters · filed 2023-08-21 | ||||
| 2022-03-31 | $1.66M 10-Q · filed 2023-05-22 | $3.72M derived: sum of 2 quarters · filed 2023-05-22 | $4.38M derived: sum of 3 quarters · filed 2023-05-22 | $4.94M derived: sum of 4 quarters · filed 2023-05-22 | ||||
| 2021-12-31 | $2.06M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $2.72M derived: sum of 2 quarters · filed 2023-03-31 | $3.28M derived: sum of 3 quarters · filed 2023-03-31 | $3.56M 10-K · filed 2023-03-31 | ||||
| 2021-09-30 | $657.10K 10-Q · filed 2022-11-14 | $1.21M derived: sum of 2 quarters · filed 2022-11-14 | $1.50M 10-Q · filed 2022-11-14 | $2.09M derived: sum of 4 quarters · filed 2022-11-14 | ||||
| 2021-06-30 | $556.53K 10-Q · filed 2022-08-15 | $838.51K 10-Q · filed 2022-08-15 | $1.44M derived: sum of 3 quarters · filed 2022-08-15 | $1.60M derived: sum of 4 quarters · filed 2022-08-15 | ||||
| 2021-03-31 | $281.98K 10-Q · filed 2022-05-20 | $880.86K derived: sum of 2 quarters · filed 2022-05-20 | $1.04M derived: sum of 3 quarters · filed 2022-05-20 | $1.19M derived: sum of 4 quarters · filed 2022-05-20 | ||||
| 2020-12-31 | $598.88K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | $756.91K derived: sum of 2 quarters · filed 2022-03-21 | $907.72K derived: sum of 3 quarters · filed 2022-03-21 | $1.06M 10-K · filed 2022-03-21 | ||||
| 2020-09-30 | $158.03K 10-Q · filed 2021-11-15 | $308.83K derived: sum of 2 quarters · filed 2021-11-15 | $458.73K 10-Q · filed 2021-11-15 | $717.40K derived: sum of 4 quarters · filed 2021-11-15 | ||||
| 2020-06-30 | $150.80K 10-Q · filed 2021-08-13 | $300.69K 10-Q · filed 2021-08-13 | $559.37K derived: sum of 3 quarters · filed 2021-08-13 | $843.87K derived: sum of 4 quarters · filed 2021-08-13 | ||||
| 2020-03-31 | $149.89K 10-Q · filed 2021-05-20 | $408.56K derived: sum of 2 quarters · filed 2021-05-20 | $693.07K derived: sum of 3 quarters · filed 2021-05-20 | |||||
| 2019-12-31 | $258.67K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | $543.18K derived: sum of 2 quarters · filed 2021-03-31 | $2.61M 10-K · filed 2021-03-31 | |||||
| 2019-09-30 | $284.50K 10-Q · filed 2020-11-16 | $2.35M 10-Q · filed 2020-11-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |